Back to Search Start Over

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX)

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX)

Authors :
Hortense Laharie-Mineur
Emilie Barbier
Anne Thirot Bidault
Côme Lepage
Romain Coriat
Eric Terrebonne
Marie-Claude Gouttebel
Jean-Baptiste Bachet
Yves Rinaldi
Patrick Texereau
Anne-Laure Pointet
David Malka
Faiza Khemissa
Alain Gratet
Julien Taieb
F. Ghiringhelli
Karine Bouhier-Leporrier
Laurent Miglianico
Source :
Journal of Clinical Oncology. 36:4107-4107
Publication Year :
2018
Publisher :
American Society of Clinical Oncology (ASCO), 2018.

Abstract

4107Background: Chemotherapy is effective in mPDAC but new approaches are still needed to improve patients (pts) survival and quality of life. We have previously published successful results of a s...

Details

ISSN :
15277755 and 0732183X
Volume :
36
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........92724253286ae1725d8be81c314eb5b5
Full Text :
https://doi.org/10.1200/jco.2018.36.15_suppl.4107